Gilead Sciences and Nurix Therapeutics extended their oncology research partnership by two years, with Nurix set to receive a $10 million extension fee. The deal adds to Nurix’s partnership momentum after a previously disclosed $7 million Pfizer milestone.
published
Gilead Sciences and Nurix Therapeutics extended their oncology research partnership by two years, with Nurix set to receive a $10 million extension fee. The deal adds to Nurix’s partnership momentum after a previously disclosed $7 million Pfizer milestone.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.